Oncology

Results from an international Phase III clinical trial presented at the 2025 ASCO Annual Meeting evaluate a treatment regimen combining encorafenib and cetuximab with mFOLFOX6 chemotherapy in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).

A new study exploring women’s body image after mastectomy sheds light on the complex emotional and psychosocial challenges these patients face during and after breast cancer treatment.

Adding nivolumab to postoperative chemoradiotherapy may reduce the likelihood of recurrence in patients with resected, high-risk head and neck squamous cell carcinoma (HNSCC), according to results from the Phase III NIVOPOSTOP trial presented at the 2025 ASCO Annual Meeting.

Patients with unresectable, locally advanced or metastatic PD-L1-positive triple-negative breast cancer (TNBC) experienced longer progression-free survival when treated with sacituzumab govitecan and pembrolizumab, compared to the current standard of chemotherapy plus pembrolizumab, according to new findings presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Second-line treatment with trastuzumab deruxtecan has been shown to extend overall survival by more than 3 months in patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (GEJA) following progression on first-line therapy, according to Phase III data from the DESTINY-Gastric04 trial presented at the ASCO 2025 Annual Meeting.

First-line maintenance treatment with lurbinectedin and atezolizumab significantly improves survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), according to primary results from the global Phase III IMforte trial presented at ASCO 2025.

A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.

A novel artificial intelligence (AI) framework called AutoRadAI has demonstrated strong diagnostic performance in detecting extracapsular extension (ECE) in prostate cancer, a key prognostic factor that can significantly impact treatment planning and surgical outcomes.